Orgenesis to Present at the 2017 Marcum MicroCap Conference
June 12, 2017 08:00 ET | Orgenesis Inc.
GERMANTOWN, MD--(Marketwired - Jun 12, 2017) - Orgenesis Inc. (OTCQB: ORGS), a vertically-integrated biopharmaceutical company with expertise and unique experience in cell therapy development and...
Orgenesis Provides Update Regarding AIP Cell-Based Therapy for Type 1 Diabetes, MaSTherCell Cell Manufacturing Subsidiary and Overall Financial Condition
March 08, 2017 09:00 ET | Orgenesis Inc.
GERMANTOWN, MD--(Marketwired - Mar 8, 2017) - Orgenesis Inc. (OTCQB: ORGS), a vertically-integrated biopharmaceutical company with expertise and unique experience in cell therapy development and...
Orgenesis Approved for Euro 12.3 Million European Grant for Further Development of Its Type 1 Diabetes Program
February 13, 2017 08:30 ET | Orgenesis Inc.
GERMANTOWN, MD--(Marketwired - Feb 13, 2017) - Orgenesis Inc. (OTCQB: ORGS), a fully-integrated cell therapy and contract development and manufacturing company, announced that its Belgian...
Servier Appoints MaSTherCell for the Development of its CAR-T Cell Therapy Manufacturing Platform
January 20, 2017 09:00 ET | Orgenesis Inc.
GERMANTOWN, MD--(Marketwired - Jan 20, 2017) -   Orgenesis Inc. (OTCQB: ORGS), a fully-integrated cell therapy and contract development and manufacturing company, announced that its...
Orgenesis CEO Vered Caplan to Present at T1D Exchange Annual Meeting
October 20, 2016 10:19 ET | Orgenesis Inc.
GERMANTOWN, MD--(Marketwired - Oct 20, 2016) - Orgenesis Inc. (OTCQB: ORGS), a fully integrated cell therapy and contract development and manufacturing company, announced that Orgenesis CEO, Vered...
Orgenesis CEO to Present at the 8th Annual Bioprocessing Summit
August 17, 2016 09:00 ET | Orgenesis Inc.
GERMANTOWN, MD--(Marketwired - Aug 17, 2016) - Orgenesis Inc. (OTCQB: ORGS), a fully-integrated cell therapy and contract development and manufacturing company, announced that Orgenesis management...
Orgenesis and Atvio Biotech Launch Joint Venture for Gene and Cell Therapy Development Services
August 01, 2016 09:00 ET | Orgenesis Inc.
GERMANTOWN, MD--(Marketwired - Aug 1, 2016) - Orgenesis Inc. (OTCQB: ORGS), a fully integrated cell therapy and contract development and manufacturing company (the "Company" or "Orgenesis") has...
Orgenesis and CureCell Awarded Grant From the KORIL Fund for Diabetes Research and Development
June 07, 2016 09:00 ET | Orgenesis Inc.
GERMANTOWN, MD--(Marketwired - Jun 7, 2016) - Orgenesis Ltd., a wholly-owned subsidiary of Orgenesis Inc. (OTCQB: ORGS), a fully integrated cell therapy and regenerative medicine company with a...
Orgenesis and Pall Corporation Receive $800,000 Grant From BIRD Foundation for Diabetes Research and Development
January 26, 2015 08:48 ET | Orgenesis Inc.
TEL AVIV, ISRAEL--(Marketwired - Jan 26, 2015) - Orgenesis Ltd., a wholly-owned subsidiary of Orgenesis Inc. (OTCQB: ORGS), a leader in the emerging fields of cellular therapy and regenerative...
Orgenesis Receives Patent for Potential Cure for Type 1 Diabetes
October 15, 2014 07:00 ET | Orgenesis Inc.
GERMANTOWN, MD--(Marketwired - Oct 15, 2014) - Orgenesis Inc. (OTCQB: ORGS), a leader in the emerging fields of cellular therapy and regenerative medicine, today announced that it has received a...